Sivik Global Healthcare LLC Buys 3,928 Shares of Stevanato Group S.p.A. (NYSE:STVN)

Sivik Global Healthcare LLC raised its holdings in shares of Stevanato Group S.p.A. (NYSE:STVN) by 5.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 80,000 shares of the company’s stock after acquiring an additional 3,928 shares during the period. Sivik Global Healthcare LLC’s holdings in Stevanato Group were worth $2,183,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Raymond James & Associates grew its position in Stevanato Group by 0.9% during the 3rd quarter. Raymond James & Associates now owns 197,316 shares of the company’s stock valued at $5,864,000 after purchasing an additional 1,806 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Stevanato Group during the 3rd quarter valued at approximately $255,000. Calamos Wealth Management LLC purchased a new stake in Stevanato Group in the 3rd quarter worth $1,456,000. Conestoga Capital Advisors LLC lifted its position in shares of Stevanato Group by 19.7% in the third quarter. Conestoga Capital Advisors LLC now owns 4,534,088 shares of the company’s stock worth $134,753,000 after buying an additional 746,136 shares in the last quarter. Finally, Fifth Third Bancorp boosted its position in shares of Stevanato Group by 70.1% during the 3rd quarter. Fifth Third Bancorp now owns 2,473 shares of the company’s stock valued at $73,000 after acquiring an additional 1,019 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. BNP Paribas began coverage on Stevanato Group in a report on Monday, April 22nd. They issued an “outperform” rating for the company. Stephens restated an “overweight” rating and set a $38.00 price objective on shares of Stevanato Group in a research note on Monday, March 25th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $30.00 price objective on shares of Stevanato Group in a report on Monday, April 22nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of €33.63 ($36.16).

Stevanato Group Price Performance

STVN stock traded up €0.62 ($0.67) on Tuesday, reaching €28.04 ($30.15). The company had a trading volume of 366,000 shares, compared to its average volume of 342,636. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.50 and a quick ratio of 1.06. The company’s fifty day moving average is €29.87 and its 200 day moving average is €29.28. Stevanato Group S.p.A. has a 1 year low of €23.00 ($24.73) and a 1 year high of €36.30 ($39.03).

Stevanato Group (NYSE:STVN) last released its quarterly earnings data on Thursday, March 7th. The company reported €0.18 ($0.19) EPS for the quarter, missing the consensus estimate of €0.19 ($0.20) by (€0.01) (($0.01)). Stevanato Group had a net margin of 13.43% and a return on equity of 14.31%. The company had revenue of €320.60 million during the quarter, compared to analysts’ expectations of €326.85 million. During the same period last year, the business earned $0.19 earnings per share. The company’s revenue for the quarter was up 9.8% compared to the same quarter last year. As a group, equities analysts forecast that Stevanato Group S.p.A. will post 0.67 EPS for the current fiscal year.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.